Login
Cardiovascular Systems NASDAQ: CSII
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
| Name | Cardiovascular Systems |
| Ticker | CSII |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Price | 35.84 |
| 52W Low/High | 27.86 / 54.18 |
| Market cap | 1.3 B |
| 1Y Total Return |
-28.21%
Below Average |
| 1Y Volatility |
56.42%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Details
| Ticker | CSII |
| Name | Cardiovascular Systems |
| ISIN | US1416191062 |
| CUSIP | 141619106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 9/18/20
| Close Price | 35.84 |
| 52W Low/High | 27.86 / 54.18 |
| Market cap | 1.3 B |
| 1Y Total Return |
-28.21%
Below Average |
| 1Y Volatility |
56.42%
Average Risk |
| Beta | 1.16 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -11.5% |
| Cash from Op. / Cur. Liabilities | -0.29 |
| Diluted Earnings / Share | -0.79 |
| ROE | - |
| ROIC | -107.8% |
| Price / Revenue | 5.2 |
| Price / Book | 4.6 |
| Price / CF | -96.2 |
| Current Ratio | 6.5 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
237
|
248
|
217
|
205
|
178
|
182
|
|
| Gross Profit |
188
|
200
|
178
|
165
|
143
|
142
|
|
| R&D |
43
|
33
|
27
|
23
|
26
|
31
|
|
| EBITDA |
-21
|
5
|
7
|
3
|
-52
|
-30
|
|
| Operating Income |
-27
|
-1
|
2
|
-2
|
-56
|
-33
|
|
| Net Income exc. Extra |
-
|
-
|
2
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
34
|
34
|
34
|
32
|
33
|
32
|
|
| EPS exc. Extra |
-0.79
|
-0.01
|
0.05
|
-0.06
|
-1.72
|
-1.04
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
340
|
219
|
203
|
194
|
142
|
171
|
|
| Cash, Eq & Invt ShortTerm |
232
|
123
|
117
|
109
|
61
|
86
|
|
| Total Current Assets |
288
|
180
|
168
|
159
|
105
|
134
|
|
| Total Non-Current Assets |
52
|
39
|
36
|
35
|
38
|
37
|
|
| Intangibles |
17
|
5
|
5
|
5
|
5
|
5
|
|
| Total Liabilities |
71
|
71
|
69
|
76
|
42
|
32
|
|
| Total Current Liabilities |
45
|
42
|
37
|
41
|
35
|
30
|
|
| Long Term Debt |
26
|
28
|
31
|
35
|
6
|
2
|
|
| Shareholder equity |
269
|
148
|
134
|
118
|
101
|
139
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-13
|
10
|
10
|
20
|
-24
|
-22
|
|
| Depreciation |
4
|
3
|
4
|
4
|
4
|
2
|
|
| Cash from Investing |
-9
|
-54
|
-5
|
-2
|
-4
|
-23
|
|
| Capex |
3
|
3
|
2
|
1
|
4
|
20
|
|
| Cash from Financing |
133
|
2
|
4
|
29
|
4
|
3
|
|
| Stock Issued |
139
|
4
|
4
|
9
|
4
|
5
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
21
|
0
|
-2
|
|
| Free Cash Flow |
-108
|
-5
|
-3
|
-3
|
-46
|
-70
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
0.8%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
433.0%
|
-
|
-
|
-
|
|
| Current Ratio |
6.5
|
4.3
|
4.5
|
3.9
|
3.0
|
4.5
|
|
| Financial Leverage D/E |
0.08
|
0.14
|
0.16
|
0.18
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-107.8%
|
1.9%
|
8.1%
|
-2.6%
|
-108.0%
|
-78.5%
|
|
| Return on Shareholder Equity |
-
|
-
|
1.4%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available